These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29028251)

  • 21. Occupational exposure to antineoplastic drugs in four Italian health care settings.
    Sottani C; Porro B; Imbriani M; Minoia C
    Toxicol Lett; 2012 Aug; 213(1):107-15. PubMed ID: 21477641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.
    Hedmer M; Tinnerberg H; Axmon A; Jönsson BA
    Int Arch Occup Environ Health; 2008 Jul; 81(7):899-911. PubMed ID: 18066576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces.
    Mucci N; Dugheri S; Farioli A; Garzaro G; Rapisarda V; Campagna M; Bonari A; Arcangeli G
    Med Pr; 2020 Sep; 71(5):519-529. PubMed ID: 32667290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination.
    Bobin-Dubigeon C; Amiand M; Percheron C; Audeval C; Rochard S; Leynia P; Bard JM
    J Anal Toxicol; 2013 Sep; 37(7):433-9. PubMed ID: 23828102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals.
    Viegas S; Pádua M; Veiga AC; Carolino E; Gomes M
    Environ Monit Assess; 2014 Nov; 186(11):7807-18. PubMed ID: 25096642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system.
    Hon CY; Teschke K; Demers PA; Venners S
    Ann Occup Hyg; 2014 Jul; 58(6):761-70. PubMed ID: 24644303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.
    Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF
    Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers.
    Delafoy C; Roussy C; Hudon AF; Cirtiu CM; Caron N; Bussières JF; Tanguay C
    J Oncol Pharm Pract; 2023 Mar; 29(2):338-347. PubMed ID: 35018847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic compounding by IV: Dispensing robot vs. manual compounding in biological safety cabinet.
    Ml H; T W; Jq Z; Yj S; Tj G; Lk Z; J L; Jf Y
    J Oncol Pharm Pract; 2022 Oct; 28(7):1487-1498. PubMed ID: 34162245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators.
    Crauste-Manciet S; Sessink PJ; Ferrari S; Jomier JY; Brossard D
    Ann Occup Hyg; 2005 Oct; 49(7):619-28. PubMed ID: 16126757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External contamination of antineoplastic drug containers from a Canadian wholesaler.
    Hilliquin D; Bussières JF
    J Oncol Pharm Pract; 2020 Mar; 26(2):423-427. PubMed ID: 31446868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual contamination in antineoplastic drug packaging.
    E Silva LS; Machado CDSB; Linden R; Antunes MV; da Silva LC; Wayhs CAY; Capp E; Ness SLR
    J Oncol Pharm Pract; 2023 Dec; 29(8):1862-1867. PubMed ID: 36659825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces.
    Hedmer M; Jönsson BA; Nygren O
    J Environ Monit; 2004 Dec; 6(12):979-84. PubMed ID: 15568047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new approach to assessing occupational exposure to antineoplastic drugs in hospital environments.
    Dugheri S; Bonari A; Pompilio I; Boccalon P; Mucci N; Arcangeli G
    Arh Hig Rada Toksikol; 2018 Sep; 69(3):226-237. PubMed ID: 30285941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations.
    Connor TH; Zock MD; Snow AH
    J Occup Environ Hyg; 2016 Sep; 13(9):658-67. PubMed ID: 27019141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results.
    Palamini M; Gagné S; Caron N; Bussières JF
    J Oncol Pharm Pract; 2020 Dec; 26(8):1921-1930. PubMed ID: 32114883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.
    Ursini CL; Cavallo D; Colombi A; Giglio M; Marinaccio A; Iavicoli S
    Int Arch Occup Environ Health; 2006 Nov; 80(2):134-40. PubMed ID: 16761155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.
    Sessink PJ; Connor TH; Jorgenson JA; Tyler TG
    J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure to antineoplastic drugs in two UK hospital pharmacy units.
    Mason HJ; Blair S; Sams C; Jones K; Garfitt SJ; Cuschieri MJ; Baxter PJ
    Ann Occup Hyg; 2005 Oct; 49(7):603-10. PubMed ID: 15964878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs).
    Dugheri S; Mucci N; Bucaletti E; Squillaci D; Cappelli G; Trevisani L; Bonari A; Cecchi M; Mini E; Ghiori A; Tognoni D; Berti N; Alderighi F; Li Vigni N; Orlandi I; Arcangeli G
    Med Pr; 2022 Dec; 73(5):383-396. PubMed ID: 36374172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.